RxDoctor Payments Data

Arkadiy Konyukhov, MD

Neurology · Elmhurst, ILNPI 1689832933

Payments from drug & device makers

$713in general payments, 2019–2025

Across 15 payments — averaging $47.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$457
  • Pfizer$67
  • Acorda Therapeutics, Inc$65
  • Bristol Myers Squibb$47
  • Novartis$38
  • Livanova USA, Inc.$21
  • plus $18 from 1 others

What the payments were for

  • Consulting fees$45063%
  • Speaking & faculty fees$659%
  • Food & beverage$17324%
  • Education$254%

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$713 in reported general payments places this provider in the 50th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$282,639
Medicare patients
796
Services billed
13,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$305,920
Kesimpta PenOfatumumab19$166,281
CopaxoneGlatiramer Acetate26$150,677
Avonex Pen (4 Pack)Interferon Beta-1a15$124,084
VumerityDiroximel Fumarate12$103,600
Emgality PenGalcanezumab-Gnlm59$55,229
Teriflunomide13$38,297
Nurtec OdtRimegepant Sulfate24$29,629
UbrelvyUbrogepant25$25,586
KeppraLevetiracetam11$22,275
Dalfampridine ErDalfampridine18$18,863
Glatiramer Acetate13$16,072
QuliptaAtogepant14$15,411
Lacosamide55$13,360
Levetiracetam328$12,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$67$340,30048 claims
BiogenVumerity$457$103,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 790 neurology providers in Illinois.

Other neurology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →